Cipla embarks on strategic expansion into Ghana

Leading global pharmaceutical company committed to providing affordable and high-quality access to medication across the continent people has officially opened a new branch in Ghana, expanding its reach and presence in the African continent.

This strategic decision reflects the company's commitment to serving the healthcare needs of the people in Ghana and contributing to the overall development of the country's healthcare sector.

Speaking with the media at Movenpick Hotel on 13th March 2024, CEO of Cipla Africa, Paul Miller, said Cipla is guided by a philosophy of 'Caring for life,' which has earned them the trust of healthcare professionals and patients worldwide.

According to him, the initial therapeutic portfolio Cipla is introducing to the Ghanaian market encompasses respiratory, gastro, cardiovascular/diabetes management, pain/colds/flu, and anti-infectives. Also, the company plans to collaborate closely with local healthcare professionals and prioritize patient education in Ghana, aiming to enhance health outcomes in the region.

Recognizing the pivotal role of investment in Africa for catalyzing job creation, infrastructure development, and sustainable economic prosperity, Cipla is determined to empower local communities and contribute to Ghana's socio-economic advancement.

Moreover, Cipla is committed to going beyond conventional pharmaceutical roles, actively engaging in corporate social responsibility initiatives.

Mr. Miller revealed, "Our philosophy is to do well while doing good. Our first corporate social investment in Ghana, through our Miles for Smiles initiative in partnership with Operation Smile, aims to fund corrective surgeries for people born with cleft conditions."

As Cipla takes strides to make a lasting impact in Ghana, Mr. Miller expressed excitement about the company's sustained commitment to creating a positive and sustainable footprint in the region.

Cipla's expansion into Ghana, it believed, signifies a potent catalyst for positive change and improved well-being across the nation in the realm of healthcare, where access and innovation intersect.

About CIPLA

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets.

Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar‟18), 4th largest in the pharma private market in South Africa (IQVIA MAT Jun‟18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work.

Our paradigm changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement.